Outcomes of Colorectal Dysplasia and Cancer in Patients with PSC-IBD Undergoing Liver Transplantation and Colectomy: Insights from a Multicenter Study

Background

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation and fibrosis of the bile ducts. It is strongly associated with inflammatory bowel disease (IBD), particularly ulcerative colitis, which predisposes affected patients to an increased risk of colorectal dysplasia and carcinoma. Managing these patients poses substantial clinical challenges, especially when both liver transplantation (LT) for end-stage liver disease due to PSC and total abdominal colectomy (TAC) for dysplasia or malignancy are indicated. Current literature guiding clinical decisions around the sequence and outcomes of these interventions remains limited. This gap underscores the need for robust data to inform surgical timing, cancer prognosis, and post-operative complication risks, including outcomes related to ileal pouch-anal anastomosis (IPAA).

Study Design

This study was a retrospective multicenter review encompassing electronic health records from nine institutions. It included adult patients with PSC and IBD who underwent liver transplantation for PSC and total abdominal colectomy for colorectal dysplasia or malignancy. The primary objective was to describe the oncological outcomes and IPAA-related complications while comparing two patient groups based on the timing of interventions: those undergoing colectomy before liver transplantation (TAC-first group) and those with liver transplantation before colectomy (LT-first group). Primary outcomes assessed included pathological staging, nodal involvement, recurrence rates, 5-year overall survival, and ileal pouch complications such as pouchitis and pouch failure.

Key Findings

Fifty patients met inclusion criteria, divided into 30 undergoing TAC for dysplasia and 20 for malignancy. No statistically significant differences were observed between TAC-first and LT-first groups regarding malignancy indication rates for colectomy (50.0% vs. 33.3%, P=0.26), T3 or greater tumor staging (50.0% vs. 25.0%, P=0.37), or distant metastases (none reported). Notably, nodal involvement was significantly higher in the LT-first group (50.0% vs. 0%, P=0.04), indicative of more advanced disease at diagnosis in these patients.

Despite more aggressive tumor characteristics in LT-first patients, colorectal cancer recurrence rates were similar between the two groups (18.2% vs. 22.2%) as was 5-year overall survival (87.5% vs. 75.0%). Kaplan-Meier analysis confirmed no significant survival difference (P=0.4), underscoring that deferral or sequencing of colectomy relative to liver transplantation may not detrimentally affect mid-term outcomes. Additionally, both groups demonstrated a comparable 54.5% incidence of pouchitis post-IPAA, consistent with previous literature, yet experienced remarkably low pouch failure rates, with only a single case recorded.

Expert Commentary

This study adds important evidence to the nuanced management of patients with PSC-IBD facing both liver failure and colorectal neoplasia. The elevated nodal involvement in the LT-first cohort suggests that clinicians often prioritize urgent liver transplantation in the context of advanced liver disease, potentially at the cost of more advanced colorectal cancer at colectomy time. However, equivalent survival outcomes indicate that appropriate multidisciplinary care and timely colectomy can mitigate oncological risks.

The rates of pouchitis parallel other IBD cohorts undergoing IPAA, signaling that PSC does not necessarily augment pouch complications beyond the baseline risk. Low pouch failure supports the continued use of restorative proctocolectomy with IPAA in this complex patient subset. Limitations include the retrospective design and relatively small sample size, common constraints in studying rare overlapping diseases requiring multiple major interventions. Further prospective and larger-scale studies are warranted to confirm these findings and optimize timing strategies.

Conclusion

In patients with concurrent PSC and IBD requiring liver transplantation and total abdominal colectomy for colorectal dysplasia or malignancy, timing of surgery—whether colectomy precedes or follows liver transplantation—did not significantly alter 5-year overall survival or cancer recurrence rates despite more advanced disease in LT-first patients. Ileal pouch complications remained consistent with prior IBD literature, with low rates of pouch failure. These findings support flexible, patient-centered timing approaches, informed by disease severity and clinical urgency, with reassurance about favorable mid-term oncological and functional outcomes. Future research should focus on refining surveillance and management protocols to further enhance prognosis and quality of life.

Funding and ClinicalTrials.gov

No specific funding was reported for this retrospective multicenter study. Clinical trial registration details were not applicable.

References

1. Galloway JL, et al. Colorectal dysplasia and malignancy outcomes in primary sclerosing cholangitis and inflammatory bowel disease requiring liver transplantation and colectomy: A multicenter study. Surgery. 2026;195:110230. doi:10.1016/j.surg.2026.05.008.
2. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis – a comprehensive review. J Hepatol. 2017;67(6):1298-1323.
3. Trivedi PJ, Adams DH, Hubscher SG. Management of primary sclerosing cholangitis and the role of liver transplantation. J Hepatol. 2017;67(3):473-484.
4. Fumery M, Xiaocang C, Dauchet L, et al. Incidence of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2017;15(5):633-642.e4.